Focused echocardiography in cardio-oncology.
cancer
cardiotoxicity focused echo
cardio‐oncology
echocardiography
Journal
Echocardiography (Mount Kisco, N.Y.)
ISSN: 1540-8175
Titre abrégé: Echocardiography
Pays: United States
ID NLM: 8511187
Informations de publication
Date de publication:
08 2020
08 2020
Historique:
received:
07
01
2020
revised:
19
03
2020
accepted:
07
07
2020
entrez:
9
12
2020
pubmed:
10
12
2020
medline:
24
6
2021
Statut:
ppublish
Résumé
Transthoracic echocardiography (TTE) is the cornerstone of imaging in patients with a malignancy in all stages of their treatment-before, during, and after the completion of it-to identify most of the cardiotoxic complications. However, the restricted time and resources of cardio-oncology services and the high volume of oncological patients and survivors on the other hand limit the access of this population to this modality. Focused Echo in Cardio-Oncology (FECO) in proportion to other focused cardiac protocols is proposed as a valuable tool after the initial standard complete TTE to: (a) identify the potential toxicity expected by the specific cancer therapy applied; (b) assess sequentially the pre-existing abnormality, if any, in relation to therapy; (c) assess the effect of any cardio-protective intervention; (d) identify any cardiac origin of patient complaints during or after therapy; (e) assess cardiac function in asymptomatic patients who develop significant changes in cardiac biomarkers during cancer therapy. Four different protocols of FECO are proposed according to the type of cardiotoxicity anticipated: FECOm (in patients on chemotherapeutics that cause myocardial dysfunction), FECOv (in patients at risk of valvular heart disease), FECOpd (in patients at risk of pericardial disease), and FECOph (in patients at risk of pulmonary hypertension). The application of FECO protocols is aimed to ensure accuracy, reliability, and effectiveness in the early identification of cardiovascular complications, improving quality of life, and being at the same time cost-effective.
Substances chimiques
Antineoplastic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1149-1158Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Euro Heart J Cardiov Imaging. 2014;15:1063‐1093.
Virani SA, Dent S, Brezden‐Masley C, et al. Canadian Cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Canad J Cardiol. 2016;32:831‐841.
Pareek N, Cevallos J, Moliner P, et al. Activity and outcomes of a cardio‐oncology service in the United Kingdom‐a five‐year experience. Eur J Heart Fail. 2018;20:1721‐1731.
Farmakis D, Keramida K, Filippatos G. How to build a cardio‐oncology service? Eur J Heart Fail. 2018;20:1732‐1734.
Lancellotti P, Suter TM, Lopez‐Fernandez T, et al. Cardio‐Oncology Services: rationale, organization, and implementation: A report from the ESC Cardio‐Oncology council. Eur Heart J. 2019;40(22):1756‐1763.
Yeh JM, Nohria A, Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model‐based estimation of the clinical and economic effects. Ann Intern Med. 2014;160:661‐671.
Wong FL, Bhatia S, Landier W, et al. Cost‐effectiveness of the children's oncology group long‐term follow‐up screening guidelines for childhood cancer survivors at risk for treatment‐related heart failure. Ann Intern Med. 2014;160:672‐683.
Gehling Bertoldi E, Marcolino MS, Rohde LEP, Luiz Ribeiro A, Polanczyk CA. Cost‐effectiveness of routine screening for cardiac toxicity in patients treated with imatinib in Brazil. Value Health Reg Issues. 2012;1:180‐183.
Nolan MT, Plana JC, Thavendiranathan P, Shaw L, Si L, Marwick TH. Cost‐effectiveness of strain‐targeted cardioprotection for prevention of chemotherapy‐induced cardiotoxicity. Int J Cardiol. 2016;212:336‐345.
Herrmann J, Lerman A, Sandhu NP, Villarraga HR, Mulvagh SL, Kohli M. Evaluation and management of patients with heart disease and cancer: cardio‐oncology. Mayo Clin Proc. 2014;89:1287‐1306.
Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur J Heart Fail. 2017;19:9‐42.
Walley PE, Walley KR, Goodgame B, Punjabi V, Sirounis D. A practical approach to goal‐directed echocardiography in the critical care setting. Crit Care (London, England). 2014;18:681.
Nielsen DL, Palshof JA, Larsen FO, Jensen BV, Pfeiffer P. A systematic review of salvage therapy to patients with metastatic colorectal cancer previously treated with fluorouracil, oxaliplatin and irinotecan +/‐ targeted therapy. Cancer Treat Rev. 2014;40:701‐715.
Sobczyk D, Nycz K, Andruszkiewicz P. Validity of a 5‐minute focused echocardiography with A‐F mnemonic performed by non‐echocardiographers in the management of patients with acute chest pain. Cardiov Ultrasound. 2015;13:16.
Neskovic AN, Hagendorff A, Lancellotti P, et al. Emergency echocardiography: the European Association of Cardiovascular Imaging recommendations. Euro Heart J Cardiov Imaging. 2013;14:1‐11.
Breitkreutz R, Price S, Steiger HV, et al. Focused echocardiographic evaluation in life support and peri‐resuscitation of emergency patients: a prospective trial. Resuscitation. 2010;81:1527‐1533.
Aagaard R, Lofgren B, Grofte T, et al. Timing of focused cardiac ultrasound during advanced life support ‐ A prospective clinical study. Resuscitation. 2018;124:126‐131.
Gunst M, Sperry J, Ghaemmaghami V, O'Keeffe T, Friese R, Frankel H. Bedside echocardiographic assessment for trauma/critical care: the BEAT exam. J Am Coll Surg. 2008;207:e1‐3.
Labovitz AJ, Noble VE, Bierig M, et al. Focused cardiac ultrasound in the emergent setting: a consensus statement of the American Society of Echocardiography and American College of Emergency Physicians. J Am Soc Echocardiogr. 2010;23:1225‐1230.
Ma IWY, Arishenkoff S, Wiseman J, et al. Internal medicine point‐of‐care ultrasound curriculum: consensus recommendations from the canadian internal medicine ultrasound (CIMUS) group. J Gen Intern Med. 2017;32:1052‐1057.
Via G, Hussain A, Wells M, et al. International evidence‐based recommendations for focused cardiac ultrasound. J Am Soc Echocardiogr. 2014;27:683.e1‐683.e33.
Lang RM, Badano LP, Mor‐Avi V, et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Euro Heart J Cardiov Imaging. 2015;16:233‐270.
Lopez‐Fernandez T, Thavendiranathan P. Emerging cardiac imaging modalities for the early detection of cardiotoxicity due to anticancer therapies. Rev Espanola Cardiol (English ed). 2017;70:487‐495.
Amit V. Cardio‐oncology: an integrated discipline or just a portmanteau. J Lancaster General Hospital. 2017;12:100‐111.
Keramida K, Farmakis D, Bingcang J, et al. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients. Eur J Heart Fail. 2019;21:529‐535.
Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA. 2003;290:2831‐2837.
Malanca M, Cimadevilla C, Brochet E, Iung B, Vahanian A, Messika‐Zeitoun D. Radiotherapy‐induced mitral stenosis: a three‐dimensional perspective. J Am Soc Echocardiogr. 2010;23(108):e1‐2.
Stewart MH, Jahangir E, Polin NM. Valvular heart disease in cancer patients: etiology, diagnosis, and management. Curr Treat Opt Cardiovasc Med. 2017;19:53.
Russo A, Novo G, Lancellotti P, Giordano A, Pinto FJ. Cardiovascular Complications in Cancer Therapy. Springer International Publishing; 2018.
Lancellotti P, Zamorano JL, Galderisi M. Anticancer Treatments and Cardiotoxicity: Mechanisms, Diagnostic and Therapeutic Interventions. USA: Elsevier Science; 2016.
Madan R, Benson R, Sharma DN, Julka PK, Rath GK. Radiation induced heart disease: Pathogenesis, management and review literature. J Egyptian Nat Cancer Inst. 2015;27:187‐193.
Lestuzzi C. Neoplastic pericardial disease: Old and current strategies for diagnosis and management. World J Cardiol. 2010;2:270‐279.
Di Liso E, Menichetti A, Dieci MV, et al. Neoplastic pericardial effusion: a monocentric retrospective study. J Palliat Med. 2019;22(6):691‐695.
Lestuzzi C, Oliva S, Ferraù F. Manual of Cardio‐oncology: Cardiovascular Care in the Cancer Patient. Cham, Switzerland: Springer International Publishing; 2017.
Ling LH, Oh JK, Schaff HV, et al. Constrictive pericarditis in the modern era: evolving clinical spectrum and impact on outcome after pericardiectomy. Circulation. 1999;100:1380‐1386.
Cherifi S, Hermans P, De Wit S, Cantinieaux B, Clumeck N. Acute pulmonary hypertension following paclitaxel in a patient with AIDS‐related primary effusion lymphoma. Clin Microbiol Infect. 2001;7:277‐278.
Savale L, Chaumais MC, O'Connell C, Humbert M, Sitbon O. Interferon‐induced pulmonary hypertension: an update. Curr Opinion Pulmon Med. 2016;22:415‐420.
McGee M, Whitehead N, Martin J, Collins N. Drug‐associated pulmonary arterial hypertension. Clin Toxicol. 2018;56:801‐809.
Lanier GM, Shah N, Garg J. Cardiotoxicity of Chemotherapeutic Agents. Nova Science Publishers, Incorporated; 2017.